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Abstract: New anti-breast cancer compounds have been found and may prove to have stronger activity. To predict the activities of 
N-benzoyl-N'-phenylthiourea (BPTU) derivatives, namely N-(3-chloro)benzoyl-N'-phenylthiourea (3-Cl-BPTU) and N-(3,4-dichloro)
benzoyl-N'-phenylthiourea (3,4-2Cl-BPTU) with Sirtuin-1 receptor (PDB code: 4I5I), molecular docking was conducted at  
the beginning of this study. The compounds were then synthesized from benzoyl chloride derivatives and N-phenylthiourea. 
Molecular structure was confirmed using  FTIR, 1H NMR, 13C NMR and Mass Spectra, while the anticancer activity was tested 
in vitro against human breast cancer cells (T47D) using MTT assay. The results indicated that the anti-cancer activities of the test 
compounds were better than those of the hydroxyurea as the reference compound, evidenced by the Rerank Score (RS). 
Furthermore, cytotoxic effect of 3-Cl-BPTU (IC50: 0.43 mM) and 3,4-dichloro-BPTU (IC50: 0.85 mM) showed better result 
compared with hydroxyurea (IC50: 4.58 mM). Therefore, we concluded that these compounds could possess termendous potential 
as the candidate for a new anticancer drug.                     
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1. Introduction  
The incidence and mortality of cancer are rapidly 
growing worldwide. The reasons are complex but 
may be attributed to both aging and growth of the 
population, as well as changes in the prevalence and 
distribution of the main risk factors for cancer, 
several of which are associated with socioeconomic 
development[1]. The types of cancers that cause major 
mortality every year are lung, stomach, colorectal, liver, 
and breast cancers. Among all those cancers, breast 
cancer becomes the most deadly cancer for women[2].  
 
 
 
 
 
 
In response to that, hydroxyurea has been widely used 
for cancer treatment as an anticancer drug. Nevertheless, 
the research data show that the antitumor activity of 
this substance does not come up with satisfying result 
due to its hydrophilic properties, which leads to poor 
membrane penetration capability. Inevitably, it is crucial 
to develop a new anticancer drug of urea and thiourea 
derivative that is more lipophilic with better membrane 
penetration  to obtain more potent activities[3–5]. In 
addition, Mc Charty[6] has synthesized and evaluated 
the anticancer activity of thiourea derivatives, 1-(4-
acetamidophenyl)-3-(4-tert-butyl benzoyl) thiourea, which 
is later named Tenovin-1. These compounds are known 
to increase p53 protein levels in vitro and inhibit SIRT1. 
Widiandani[7] has also proven the anti breast-cancer 
activity of T47D cells of the N-(allylcarbamothioyl) 
benzamide compound.  
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In the present study, the structure of N-benzoyl-N'-
phenylthiourea (BPTU) compound was modified by 
adding chloro substituent to the benzoyl moiety. Two 
compounds were proposed, namely N-(3-chloro)benzoyl-
N'-phenylthiourea (3-Cl-BPTU) and N-(3,4-dichloro)
benzoyl-N'-phenylthiourea  (3,4-2Cl-BPTU)  (Fig.  1). 
Addition of phenyl groups and chloro-substituent at 
benzoyl moiety will improve the lipophilic and electronic 
properties of the compound. As a result, the binding 
affinity of the ligand to receptor will increase[8–10]. 
Previously, several BPTU compounds have been 
synthesized and shown their cytotoxic activity to T47D 
cells[11]. These breast cancer cells are used because they 
express the mutated p53 protein[12]. Within the present 
study, we performed the activity predictions by molecular 
docking of test compounds against Histon deacetylase 
SIRT1 inhibitor (PDB: 4I5I) using Molegro Virtual 
Docker 5.5[13]. This receptor plays an important role in 
the growth of tumor cells[14,15].  
The test compounds were synthesized from N-
phenylthiourea with benzoyl chloride derivatives (3-Cl 
and 3,4-2Cl) using acyl nucleophilic substitution 
reactions[16,17]. The structures of the synthesis compounds 
were identified using IR, 1H NMR, 13C NMR and mass 
spectrometers[18]. 
The anticancer activity of the test compound was 
determined through cytotoxic assay using MTT method 
(3-(4,5-dimetylthiazol-2-il)-2,5-diphenyltetrazolium 
bromide) in vitro on T47D breast cancer cells and Vero 
normal cells. The result of anticancer activity test on T47D 
cells was obtained as IC50 and compared with hydroxyurea, 
as well as observed in Vero normal cells[12,19]. 
It is expected to obtain a candidate of anticancer drug 
from the new class of thiourea derivatives that have 
potent anticancer activity on breast cancer cells T47D. 
This study will proceed with the synthesis of other 
N-benzoyl-N'-phenylthiourea (BPTU) derivatives to 
obtain QSAR equation and molecular mechanism test, 
before preclinical and clinical trials. 
2. Materials and methods 
2.1. Materials and tools 
Materials for synthesis included N-phenylthiourea, 
benzoyl chloride derivatives (3-Cl and 3,4-2Cl) (Sigma 
Aldrich), tetrahydrofuran (THF), triethylamine (TEA), 
acetone, ethyl acetate, n-hexane, chloroform and 
ethanol, and those for activity test included 3-Cl-BPTU; 
3,4-2Cl-BPTU and HU compounds, T47D and Vero cell 
cultures, culture media RPMI and M199, buffer saline 
phosphate (PBS), FBS (fetal bovine serum), tripsin, 
penicillin-streptomycin, fungizon, DMSO, MTT(3-(4,5-
dimethyltiazole-2-yl)-2,5-diphenyltetrazolium bromide) 
0.5 mg/mL, SDS 10% in HCl 0.01 N. 
Corning Hot Plate P351, Fisher-John Electrothermal 
Mel-Temp, Jasco FT-IR 5300 Spectrophotometer, 1H NMR 
Spectrometer and 13C NMR Agilent 500 MHz with DD2 
console system at 500 MHz (1H) and 125 MHz (13C), 
Mass Waters Spectrometer were used in the present study. 
Tool for cytotoxic test included 5% CO2 incubator, LAF, 
micropipet, test tube, vortex, 96-well microplate, Conical 
tube, inverter microscope, hemocytometer, ELISA-reader. 
Tools for molecular modeling included ChemBioDraw 
Ultra 15.0, Molegro Virtual Docker (MVD) 5.5. 
C
O
N
H
C
N
H
S
Cl
C
O
N
H
C
N
H
S
Cl
Cl
N
H
O
NH2
HO
(a) 3-Cl-BPTU                                           (b) 3,4-2Cl-BPTU  
 
 
 
                                     (c)  HU  
Figure 1.  Structures of  3-Cl-BPTU (a); 3,4-2Cl-BPTU (b) and HU 
(c) compounds.  
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2.2. Methods 
2.2.1. Molecular modeling 
Activity prediction was conducted with molecular 
modeling of N-(3-chloro)benzoyl-N'-phenylthiourea and 
N-(3,4-dichloro)benzoyl-N'-phenylthiourea by docking 
with Histon deacetylase SIRT1 inhibitor PDB code: 
4I5I followed by Software Molegro Virtual Docker 5.5., 
and hydroxyurea was used as reference compound. 
2.2.2. Synthesis of 3-Cl-BPTU; 3,4-2Cl-BPTU 
compounds 
Synthesis of N-(3-chloro)benzoyl-N'-phenylthiourea 
and N-(3,4-dichloro)benzoyl-N'-phenylthiourea compounds: 
In the round flask, N-phenylthiourea was mixed with 
tetrahydrofuran and TEA. Benzoyl chloride derivatives 
(3-Cl; 3,4-2Cl) solution was added to tetrahydrofuran, 
and the mixture was incubated in the ice bath. It was 
added gradually through a dropping funnel and stirred 
with a magnetic stirrer. The mixture was refluxed and 
stirred on top of a water bath. Just as a single spot 
appeared in the TLC , the reaction was terminated. THF 
was then completely evaporated on the rotary evaporator 
before recrystallization process started[7]. 
The identification of the structure of the synthesized 
compounds was performed based on the results of 
the examination: Infrared, 1H NMR, 13C NMR and 
HRMS[18]. 
2.2.3. Cytotoxicity test of MTT assay method 
The test started with the distribution of T47D and 
M199 cells into 96-well plates 24 h prior to incubation in 
5% CO2 incubators, followed by adding test solutions, 
positive and negative controls in various concentration 
series. Each concentration was replicated for three 
times. Wells with no cells were filled with media as 
media controls and then re-incubated for 24 h. Before 
incubation ended, each well was added with 0.5 mg/mL 
of MTT up to 100 μL. The incubation proceeded 
for 3 h, and then the MTT reaction was discontinued 
by adding 100 μL SDS 10% in 0.01 N HCI to each 
hole. The microplate  was wrapped in paper and 
incubated at 37 ºC for 24 h. The live cells converted 
MTT into a dark blue formazan. To identify the 
absorption at λ = 595 nm, ELISA reader was employed, 
and the IC50 values of the two test compounds as well 
as the reference compound were determined by using 
probit analysis[12].  
3. Results and discussion   
The RS values could describe drug activities in silico 
accordingly. On the basis of in silico test results as 
shown on Table 1, the RS of 3-Cl-BPTU compound 
was –120.4530. The RS of 3,4-2Cl-BPTU compound 
was –116.3190, and the RS of HU compound was 
–40.0237. The smaller the RS value is, the more stable 
the resulting drug-receptor interaction is, which corresponds 
to larger activity[20]. Table 2 and Figure 2 indicate the 
number and type of amino acids residues in the binding 
site. Based on the data, 3-Cl-BPTU compound had the 
largest number of hydrogen and steric bonds (van der 
Waals and Hydrophobic). This conclusion indicated 
that the anticancer activity of 3-Cl-BPTU compound 
was the best among the proposed compounds. 
Two new compounds, namely: N-(3-chloro)benzoyl-
N'-phenyltiourea and N-(3,4-dichloro) benzoyl-N'-
phenyltiourea, were synthesized from benzoyl chloride 
derivatives with N-phenylthiourea in one step. The two 
compounds were yellow solids and insoluble in water. 
The structure of the compound was synthesized and 
identified by IR spectroscopy, 1H NMR, 13C NMR, 
and HRMS as follows: 
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Figure 2. Ligand interaction with amino acids at the EGFR binding site where hydrogen bonds are indicated by blue dashed-lines and steric 
interruptions shown by red dashed-lines (a) 3,4-2Cl-BPTU compound, (b) 3-Cl-BPCT compound and (d) HU reference compound.  
                 (a) 3,4-2Cl-BPTU                                                            (b) 3-Cl-BPTU                                                                  (c)  HU  
Table 1. Rerank score (RS) value.  
Compounds RS, PDB code: 4I5I (kcal/mol) 
3-Cl-BPTU –120.4530 
3,4-2Cl-BPTU –116.3190 
HU –40.0237 
 Compounds 
Amino Acids 
Ala262 Asp272 Asp348 Ile270 Ile347 Phe273 Pro271 Ser265 Val266 
3-Cl-BPTU 4S 4S 1H/1S 5S 1H 5S 6S 1S 1S 
3,4-2Cl-BPTU 3S 3S 1H/1S 5S 1H 4S 5S 1S 1S 
Hydroxyurea 1S – 2H – 1H – – – – 
Table 2. Hydrogen and steric bonds performed by the interaction between tested compounds and amino acids in the binding site of SIRT1.  
H: Hydrogen bond and S: Steric bond (Van der Waals and Hydrophobic).  
Figure 3. Reaction on the synthesis of N-benzoyl-Nʹ-phenylthiourea or N-(phenylcarbamothioyl)-benzamide derivatives.  
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3.1. N-(3-chloro)benzoyl-N'-phenyltiourea (3-Cl-BPTU) 
Yellow crystal, m.p. 119 ºC. 1H NMR (CDCl3, 500 MHz) 
δ: 7.24 (t, J = 7.2 Hz, 1H, Ar-H); 7.39 (dd, J1 = 7.2 Hz, 
J2 = 8.0 Hz, 2H, Ar-H); 7.52 (t, J = 8.0 Hz, 1H, Ar-H); 
7.66 (d, J = 8.0 Hz, 1H, Ar-H); 7.67 (d, J = 8.0 Hz, 
2H, Ar-H); 7.88 (d, J = 8.0 Hz, 1H, Ar-H); 7.99 (s, 1H, 
Ar-H); 11.75 (s, 1H, O=C-NH-C=S); 12.46 (s, 1H, 
S=C-NH-Ar). 13C NMR (CDCl3, 125 MHz) δ: 124.84 
(1C, Ar); 126.90 (2C, Ar); 127.95 (1C, Ar); 129.01 
(1C, Ar); 129.22 (2C, Ar); 130.86 (1C, Ar); 133.29 
(1C, Ar); 133.66 (1C, Ar); 134.76 (1C, Ar); 138.49 
(1C, Ar); 167.42 (1C, C=O); 179.47 (1C, C=S). IR 
(KBr), ν maks (cm–1): 1672 (C=O amide); 1672, 1451 
(C=C Ar); 3219, 1592 (NH strech sec.amides); 1085, 811 
(C=S). HRMS (m/z) C14H10N2OSCl: (M-H)
–: 289.0200, 
Calc. Mass: 289.0202. δ m/z = 0.0002<0.005. 
3.2. N-(3,4-dichloro)benzoyl-N'-phenyltiourea 
(3,4-2Cl-BPTU) 
Yellow crystal, m.p. 140 ºC. 1H NMR (CDCl3, 500 MHz) 
δ: 7.30 (t, J = 7.4 Hz, 1H, Ar-H); 7.43 (t, J = 7.4 Hz, 2H, 
Ar-H);  7.63 (d, J = 8.3 Hz, 1H, Ar-H); 7.69 (d, J = 7.4 Hz, 
2H, Ar-H); 7.72 (dd, J1 = 8.3 Hz, J2 = 2.2 Hz, 1H, 
Ar-H); 8.02 (d, J = 2.2 Hz, 1H, Ar-H); 9.06 (s, 1H, 
O=C-NH-C=S); 12.40 (s, 1H, S=C-NH-Ar); 13C NMR 
(CDCl3, 125 MHz) δ: 124.28 (2C, Ar); 126.42 (1C, Ar); 
127.28 (1C, Ar); 129.13 (1C, Ar); 129.96 (2C, Ar); 
131.41 (1C, Ar); 131.49 (1C, Ar); 134.26 (1C, Ar); 
137.51 (1C, Ar); 138.75 (1C, Ar); 164.88 (1C, C=O); 
178.04 (1C, C=S). IR (KBr), ν maks (cm–1): 1644 
(C=O amide); 1608, 1496 (C=C Ar); 3216, 1608 
(NH strech sec.amides); 1083, 816 (C=S). HRMS (m/z) 
C14H9N2OSCl2: (M-H)
–: 322.9818, Calc. Mass: 322.9813. 
δ m/z = 0.0005<0.005. 
4. Conclusions 
This study showed that two new compounds of 
N-benzoyl-N'-phenylthiourea (BPTU) derivatives, namely: 
N-(3-chloro)benzoyl-N'-phenylthiourea (3-Cl-BPTU) and 
N-(3,4-dichloro)benzoyl-N'-phenylthiourea (3,4-2Cl-BPTU) 
were successfully synthesized and showed higher in vitro 
anticancer activity against human breast cancer cells 
(T47D) compared with hydroxyurea anticancer drugs 
(Fig. 4). Furthermore, in silico study indicated that better 
inhibitory activity was related to a higher affinity with 
SIRT1 binding sites. The value of IC50 in N-(3-chloro) 
Figure 4. T47D cells before administration of a test compound: living cells condition (a) and red arrow shows: T47D cells after administration of 
a test compound (3-Cl-BPTU) with a dose of 500 μg/mL: the presence of dead cells after administration of a test compound (3-Cl-BPTU) (b).  
 (a)  (b) 
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benzoyl-N'-phenylthiourea was 0.43 mM and in 
N-(3,4-dichloro)benzoyl-N'-phenylthiourea was 0.85 mM, 
which was more active than the value in hydroxyurea 
(4.58 mM) (Table 3). These two new compounds were 
more compatible to binding enzymes compared with 
hydroxyurea, as they illustrated better inhibitory activities. 
It was predicted that the activities of these two new 
compounds were cell-targetted because they had toxic 
effects on cancer cells but were not toxic to Vero 
normal cells. Collectively, it is necessary to examine the 
molecular mechanisms of these two new compounds.  
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Author correction: 
The authors regret to find that there is an error in the Figure 3(E) of their previously published paper 
(The adsorption of cellular proteins affects the uptake and cellular distribution of gold nanoparticles. 
2016, 25 (9): 651–659) due to the negligence in the process of assembling pictures. Although it does not 
affect the conclusion of the study, it is an obvious mistake. The authors have now modified the Figure 3(E) 
as below: 
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